Address: ul. Pelplińska 19
83-200 Starogard Gdański
Tel: +48 58 563 16 00
Polpharma SA belongs to the select group of leaders in the pharmaceutical industry in Poland. For 75 years it has enjoyed the trust of patients, doctors and business partners.
Polpharma was established in 1935. In 2000 it was privatised with the participation of exclusively Polish capital. Polpharma’s strength is the combination of many years of experience with modern technologies and the highest standards of management.
Polpharma is currently the largest Polish manufacturer of generic drugs and pharmaceutical substances. It produces a wide range of prescription drugs and drugs used in inpatient care. The company specialises in preparations used in cardiology, gastroenterology and neurology. A significant part of Polpharma’s portfolio contains also OTC drugs.
Polpharma is the majority shareholder in Medana Pharma S.A. from Sieradz, which is the leader in the area of manufacture of paediatric drugs and vitamin preparations in modern forms. Medana’s portfolio includes also dermatological drugs and drugs used in motor organ disorders, as well as dietary supplements.
In July 2010, Polpharma took over from Bioton SA the part of the company dealing with the manufacture and sale of antibiotics.
For years Polpharma has been the market leader in Poland. In many countries the arrival of multinational companies (MNCs) led to the loss of leadership by the historical players to…
Sabina Sampławska, director, head of life sciences at KPMG Poland, discusses the challenge of pricing pressures and how their innovative services help companies manage this trend, as well as the…
Michael Kern, director general of the German Chamber of Commerce in Poland, discusses the evolving economic and business landscape in Poland and the overall impact of German companies. Furthermore, he…
Adam Czerw, country manager of LEO Pharma Poland, discusses the impressive growth of the affiliate, especially since the global 2016 purchase of Astellas’ dermatology portfolio, as well as the encouraging…
Michał Pietraszek, general manager of Apotex Poland, the leading Canadian generics powerhouse, discusses the affiliate’s strategic move into the OTC and food supplement business and the company’s niche-market approach to…
Michael Dembinski, chief advisor of the British Polish Chamber of Commerce, discusses the important role of the chamber in driving forward Polish clinical trials and the challenges in unlocking Poland’s…
Mirosław Wysocki, national consultant in the area of Public Health, professor at the National Institute of Public Health (NIH), the research institute responsible inter alia for health promotion and disease…
Monika Constant, director general of the French-Polish Chamber of Commerce in Poland (CCIFP), discusses the evolution of the two nations’ bilateral business relationship, the benefits of conducting business in Poland,…
Beata Ambroziewicz, board member of the Polish cancer patient coalition, an umbrella organization that encompasses 41 Polish cancer organizations, discusses the challenges and possible solutions in regard to hospital care…
Bogna Cichowska-Duma, general director of the Employers’ Association of Innovative Pharmaceutical Companies (INFARMA), the voice of 28 leading innovative companies in Poland, discusses the challenges and opportunities for doing research…
Marcin Czech, deputy minister and undersecretary of state at the Polish Ministry of Health, provides an in-depth perspective on Poland’s drug policy framework and the new medicines policy that aims…
Mirosław Zieliński, president of the Polish National Forum for the Therapy of rare diseases (ORPHAN), the representative voice for 35 Polish rare disease associations, discusses the implications of the introduction…
Wojciech Kuta, editor-in-chief of Rynek Zdrowia, a leading Polish healthcare publication, discusses the interacting dynamics of the obstacles facing Polish healthcare, as the country aims to increase healthcare spending to…
See our Cookie Privacy Policy Here
